For the superior efficacy of FGF21in handling metabolic diseases, including HP, thus improving FGF21 resistance is a new idea for the treatment of obesity and related metabolic disease. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.